

**TSH BIOPHARM CORPORATION LTD.
AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
AND INDEPENDENT AUDITORS' REVIEW REPORT
FOR THE NINE MONTHS ENDED
SEPTEMBER 30, 2024 AND 2023**

Address : 3F.-1, No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)

Telephone No. : 02-26558525

For the convenience of readers and for information purpose only, the independent auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and financial statements shall prevail.

Table of contents

Contents	Page
1.Cover Page	1
2.Table of Contents	2
3.Independent Auditors' Review Report	3~4
4.Consolidated Balance Sheets	5
5.Consolidated Statements of Comprehensive Income	6
6.Consolidated Statements of Changes in Equity	7
7.Consolidated Statements of Cash Flows	8~9
8.Notes to the Consolidated Financial Statements	10
(1) History and organization	10
(2) Approval date and procedures of the financial statements	10
(3) Application of new standards, amendments and interpretations	10~12
(4) Summary of significant accounting policies	12~14
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	14
(6) Explanation of significant accounts	14~38
(7) Related-party transactions	38~40
(8) Pledged assets	40
(9) Significant commitments and contingencies	40
(10) Losses due to major disasters	40
(11) Significant subsequent events	40
(12) Other	40~41
(13) Other disclosures	41
A. Information on significant transactions	41~43
B. Information on investees	43-44
C. Information on investment in mainland China	44
D. Information on major shareholders	44
(14) Segment information	44~45

INDEPENDENT AUDITORS' REVIEW REPORT

To the Board of Directors of TSH Biopharm Corporation Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of TSH Biopharm Corporation Ltd. and its subsidiaries (the "Group") as of September 30, 2024 and 2023, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months and nine months ended September 30, 2024 and 2023, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and International Accounting Standard (IAS) No.34, "Interim Financial Reporting" as endorsed by the Financial Supervisory Commission (FSC) of the Republic of China. Our responsibility is to express a conclusion on these interim the financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity". A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as of September 30, 2024 and 2023, and of its consolidated financial performance and its cash flows for the three months and nine months ended September 30, 2024 and 2023, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Emphasis of Matter Paragraph

As Note 4(2), TSH Biopharm Corporation Ltd.(the Company) participated in cash capital increase of Chuang Yi Biotech Co. Ltd. on November 24, 2023. The Company has cumulatively acquired 51.6% of

Chuang Yi Biotech Co. Ltd., and took control and become the parent company. Since TTY Biopharm Company Limited is the ultimate parent entity of the Company and Chuang Yi Biotech Co. Ltd., referring to the regulations of the Accounting Research and Development Foundation's IFRS Q&A, the aforementioned transaction is an organizational reorganization under common control, and regarded as an acquisition from the beginning. The Company restated the consolidated financial statements for the nine months ended September 30, 2023. The auditor did not modify the conclusion due to this matter.

KPMG

Taipei, Taiwan (Republic of China)

November 8, 2024

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)
TSH Biopharm Corporation Ltd. and Subsidiaries
Consolidated Balance Sheets
September 30, 2024, December 31, 2023 and September 30, 2023
(Expressed in thousands of New Taiwan Dollars)

	30-Sep-24		31-Dec-23		30-Sep-23			30-Sep-24		31-Dec-23		30-Sep-23	
	Amount	%	Amount	%	Amount	%		Amount	%	Amount	%	Amount	%
Assets							Liabilities and Equity						
Current assets:							Current liabilities:						
1100 Cash and cash equivalents (notes 6(1) 、(5) and (21))	\$ 585,106	31	576,585	41	566,172	38	2130 Contract liabilities-current (note 6(18))	\$ 3,436	-	1,842	-	3,943	-
1120 Current financial assets at fair value through other comprehensive income (notes 6(2) 、(21) and 13)	98,307	5	79,228	6	72,384	5	2150 Notes payable (note 6(5) 、(21))	13,275	1	446	-	263	-
1150 Notes receivable, net (notes 6(3) 、(5) 、(18) and (21))	11,363	-	14,471	1	14,639	1	2170 Accounts payable (note 6(5) 、(21))	17,968	1	6,730	1	13,923	1
1170 Accounts receivable, net (notes 6(3) 、(5) 、(18) and (21))	316,934	17	193,095	14	247,058	17	2180 Accounts payable to related parties (notes 6(21) and 7)	115,932	6	44,248	3	130,559	9
1180 Accounts receivable from related parties (notes 6(3) 、(18) 、(21) and 7)	3,534	-	766	-	2,666	1	2200 Other payables (notes 6(11) 、(21) and 7)	88,353	5	66,738	5	64,987	5
1220 Current income tax assets	144	-	34	-	18	-	2230 Current income tax liabilities (note 6(5))	19,739	1	2,972	-	4,568	-
1200 Other receivables (notes 6 (21))	38,718	2	2,141	-	2,252	-	2280 Current lease liabilities (notes 6(5) 、(13) 、(21) 、(24) and 7)	7,453	-	7,397	1	7,403	1
130x Inventories (note 6(4) 、(5))	172,607	9	118,395	9	149,973	10	2322 Long-term borrowings-current portion (notes 6(12) 、(21) 、(24) and 7)	-	-	-	-	14,354	1
1410 Prepayments	13,792	1	9,294	1	11,581	1	2300 Other current liabilities (note 6(5))	2,406	-	3,253	-	3,807	-
1476 Other financial assets-current (notes 6(1) 、(5) 、(10)and (21))	127,000	7	116,309	8	116,829	8		268,562	14	133,626	10	243,807	17
1479 Other current assets –other (notes 6(10) and 7)	1,274	-	3,441	-	2,544	-							
	1,368,779	72	1,113,759	80	1,186,116	81	Non-current liabilities:						
							2580 Non-current lease liabilities (notes 6(5) 、(13) 、(21) 、(24) and 7)	5,305	-	-	-	1,825	-
Non-current assets:							Total liabilities						
1517 Non-current financial assets at fair value through other comprehensive income (notes 6(2) 、(21) and 13)	183,009	10	182,475	13	184,768	12		273,867	14	133,626	10	245,632	17
1600 Property, plant and equipment (note 6(5) 、(7))	26,183	1	25,359	2	26,131	2	Equity (note 6(16)) :						
1755 Right-of-use assets (note 6 (5) 、(8))	12,694	1	7,316	1	9,145	1	3100 Capital stock	383,981	20	383,981	27	383,981	26
1780 Intangible assets (note 6 (5) 、(9))	294,505	16	53,636	4	56,264	4	3200 Capital surplus	459,554	24	459,500	33	459,511	31
1840 Deferred income tax assets	1,509	-	1,509	-	1,800	-	Retained earnings :						
1915 Prepayment for equipment	3,186	-	3,151	-	2,596	-	3310 Legal reserve	126,073	7	121,910	9	121,910	8
1920 Refundable deposits paid (notes 6(10) 、(21) and 7)	9,107	-	6,237	-	5,293	-	3320 Special reserve	-	-	4,417	-	4,417	-
1995 Other non-current assets (notes 6(5) 、(10) and 9)	6,417	-	6,417	-	6,417	-	3350 Unappropriated retained earnings	344,996	18	82,232	6	93,194	7
	536,610	28	286,100	20	292,414	19	3400 Other equity	88,165	5	55,560	4	51,241	3
							Equity attributable to owners of the parent company	1,402,769	74	1,107,600	79	1,114,254	75
							35xx Equity attributable to former owner of business combination under common control	-	-	-	-	41,739	3
							36xx Non-controlling interest (note 6(5) 、(6))	228,753	12	158,633	11	76,905	5
							Total equity	1,631,522	86	1,266,233	90	1,232,898	83
Total assets	\$ 1,905,389	100	1,399,859	100	1,478,530	100	Total liabilities and equity	\$ 1,905,389	100	1,399,859	100	1,478,530	100

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)
TSH Biopharm Corporation Ltd. and Subsidiaries
Consolidated Statements of Comprehensive Income
For the three months and nine months periods ended September 30, 2024 and 2023
(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)

	Three months periods ended September				Nine months periods ended September				
	30		30		30		30		
	2024	%	2023	%	2024	%	2023	%	
	AMOUNT		AMOUNT		AMOUNT		AMOUNT		
4000	Operating revenue (notes 6(18) and 7)	\$ 388,532	100	269,420	100	824,613	100	584,557	100
5000	Operating costs (notes 6(4) and 7)	200,212	52	143,069	53	387,434	47	286,655	49
	Gross profit	188,320	48	126,351	47	437,179	53	297,902	51
6000	Operating expenses (notes 6(3) 、(13) 、(14) 、(19) 、7 and 12):								
6100	Selling expenses	79,614	19	62,188	23	172,941	21	161,572	28
6200	Administrative expenses	28,037	7	24,158	9	99,607	12	69,860	12
6300	Research and development expenses	5,987	2	5,956	2	21,050	2	20,829	3
6450	Expected credit losses (gain on reversal)	903	-	33	-	1,693	-	(1,860)	-
		114,541	28	92,335	34	295,291	35	250,401	43
	Operating income	73,779	20	34,016	13	141,888	18	47,501	8
	Non-operating income and expenses (notes 6(13) 、(20) and 7):								
7100	Interest income	542	-	957	-	2,394	-	4,786	1
7010	Other income	233	-	46	-	673	-	162	-
7020	Other gains and losses	5,692	1	7,198	3	6,135	1	6,917	1
7050	Finance costs	(165)	-	(116)	-	(311)	-	(575)	-
		6,302	1	8,085	3	9,431	1	11,290	2
	Profit before tax	80,081	21	42,101	16	151,319	19	58,791	10
7950	Less : Income tax expense (note 6(15))	(8,730)	(2)	(4,721)	(2)	(29,213)	(4)	(12,663)	(2)
	Profit for the year	71,351	19	37,380	14	122,106	15	46,128	8
8300	Other comprehensive income								
8310	Components of other comprehensive income that will not be reclassified to profit or loss								
8316	Unrealized gains (losses) from investments in equity instruments at fair value through other comprehensive income	47,392	12	538	-	240,733	29	35,462	6
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Components of other comprehensive income that will not be reclassified to profit or loss	47,392	12	538	-	240,733	29	35,462	6
8360	Components of other comprehensive income that may be reclassified subsequently to profit or loss								
8361	Exchange differences on translation of foreign financial statements	36	-	68	-	93	-	3	-
8399	Income tax related to components of other comprehensive income that may be reclassified to profit or loss	-	-	-	-	-	-	-	-
8300	Other comprehensive income (after tax)	47,428	12	606	-	240,826	29	35,465	6
8500	Total comprehensive income	\$ 118,779	31	37,986	14	362,932	44	81,593	14
	Profit attributable to:								
8610	Equity holders of the parent company	\$ 48,539	13	16,838	6	103,484	13	45,794	8
8615	Equity attributable to former owner of business combination under common control	-	-	10,599	4	-	-	172	-
8620	Non-controlling interest	22,812	6	9,943	4	18,622	2	162	-
		\$ 71,351	19	37,380	14	122,106	15	46,128	8
	Total comprehensive income attributable to:								
8710	Equity holders of the parent company	\$ 95,950	25	17,376	6	344,265	42	81,256	14
8715	Equity attributable to former owner of business combination under common control	-	-	10,635	4	-	-	174	-
8720	Non-controlling interest	22,829	6	9,975	4	18,667	2	163	-
		\$ 118,779	31	37,986	14	362,932	44	81,593	14
	Earnings per share (note 6(17))								
9750	Basic earnings per share	\$ 1.26		0.44		2.70		1.19	
9850	Diluted earnings per share	\$ 1.26		0.44		2.69		1.19	

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)
TSH Biopharm Corporation Ltd. and Subsidiaries
Consolidated Statements of Changes in Equity
For the nine months periods ended September 30, 2024 and 2023
(Expressed in Thousands of New Taiwan Dollars)

	Retained Earnings					Other Equity Interest		Equity attributable to owners of the parent company	Equity attributable to former owner of business combination under common control	Non-controlling interest	Total equity
	Ordinary share capital	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings	Cumulative translation differences of foreign operations	Unrealized gain(loss) on financial assets at fair value through other comprehensive income				
Balance at January 1, 2023	\$ 383,981	459,435	115,721	-	112,647	-	(4,417)	1,067,367	-	-	1,067,367
Retrospective adjustment of equity attributable to former owner of business combination under common control	-	-	-	-	-	-	26,992	26,992	41,565	76,742	145,299
Balance at January 1, 2023 after retrospective adjustment	383,981	459,435	115,721	-	112,647	-	22,575	1,094,359	41,565	76,742	1,212,666
Net income for the period	-	-	-	-	45,794	-	-	45,794	172	162	46,128
Other comprehensive income for the period	-	-	-	-	-	-	35,462	35,462	2	1	35,465
Total comprehensive income for the period	-	-	-	-	45,794	-	35,462	81,256	174	163	81,593
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	6,189	-	(6,189)	-	-	-	-	-	-
Special reserve appropriated	-	-	-	4,417	(4,417)	-	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(61,437)	-	-	(61,437)	-	-	(61,437)
Other changes in capital surplus	-	76	-	-	-	-	-	76	-	-	76
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	-	-	-	6,796	-	(6,796)	-	-	-	-
Balance at September 30, 2023	\$ 383,981	459,511	121,910	4,417	93,194	-	51,241	1,114,254	41,739	76,905	1,232,898
Balance at January 1, 2024	\$ 383,981	459,500	121,910	4,417	82,232	(233)	55,793	1,107,600	-	158,633	1,266,233
Net income for the period	-	-	-	-	103,484	-	-	103,484	-	18,622	122,106
Other comprehensive income for the period	-	-	-	-	-	48	240,733	240,781	-	45	240,826
Total comprehensive income for the period	-	-	-	-	103,484	48	240,733	344,265	-	18,667	362,932
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	4,163	-	(4,163)	-	-	-	-	-	-
Special reserve appropriated	-	-	-	-	(49,150)	-	-	(49,150)	-	-	(49,150)
Cash dividends of ordinary share	-	-	-	(4,417)	4,417	-	-	-	-	-	-
Other changes in capital surplus	-	54	-	-	-	-	-	54	-	-	54
Increase in non-controlling interest	-	-	-	-	-	-	-	-	-	51,453	51,453
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	-	-	-	208,176	-	(208,176)	-	-	-	-
Balance at September 30, 2024	\$ 383,981	459,554	126,073	-	344,996	(185)	88,350	1,402,769	-	228,753	1,631,522

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)
TSH Biopharm Corporation Ltd. and Subsidiaries
Consolidated Statements of Cash Flows
For the nine months periods ended September 30, 2024 and 2023
(Expressed in Thousands of New Taiwan Dollars)

	Nine months periods ended September 30	
	2024	2023
Cash flows from operating activities:		
Profit before tax	\$ 151,319	58,791
Adjustments:		
Adjustments to reconcile profit		
Depreciation	13,755	8,117
Amortization	7,990	8,692
Expected credit losses (gain on reversal)	1,693	(1,860)
Interest expense	311	575
Interest income	(2,934)	(4,786)
Dividends income	(6,528)	(6,464)
Losses on disposal and write-off of property, plant and equipment	192	17
Profit from lease modification	(1)	-
Total adjustment to reconcile profit	14,478	4,291
Changes in operating assets and liabilities:		
Decrease in notes receivable	7,715	1,496
Increase in accounts receivable (including related parties)	(72,131)	(61,454)
Decrease in other receivables	13	234
Increase in inventories	(41,443)	(42,583)
Increase in prepayments	(1,496)	(1,783)
Decrease in other current assets	2,716	3,029
Increase (decrease) in contract liabilities	1,594	(1,489)
Increase (decrease) in notes payable	11,315	(470)
Increase in accounts payable (including related parties)	35,940	87,579
Increase (decrease) in other payables-related parties	13,178	(14,673)
Decrease in other current liabilities	(1,313)	(4,640)
Total changes in operating assets and liabilities	(43,912)	(34,754)
Total adjustments	(29,434)	(30,463)
Cash flows from operations	121,885	28,328
Interest received	4,395	4,130
Interest paid	(311)	(638)
Income tax paid	(19,094)	(16,128)
Net cash flows from operating activities	106,875	15,692

(Continued)

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)
TSH Biopharm Corporation Ltd. and Subsidiaries
Consolidated Statements of Cash Flows
For the nine months periods ended September 30, 2024 and 2023
(Expressed in Thousands of New Taiwan Dollars)

	Nine months periods ended September 30	
	2024	2023
Cash flows from (used in) investing activities:		
Disposal of financial assets measured at fair value through other comprehensive income	183,100	9,121
Net cash flow from acquisition of subsidiaries	(242,870)	-
Acquisition of property, plant and equipment	(847)	(1,766)
Disposal of property, plant and equipment	250	-
Increase (decrease) in guarantee deposits paid	109	(478)
Acquisition of intangible assets	(643)	(177)
Decrease in other financial assets - current	14,309	158,224
Decrease (increase) in other non-current financial assets	-	(6,333)
Increase in prepayment for equipment	(35)	(2,501)
Dividends received	6,528	6,464
Net cash flows from (used in) investing activities	(40,099)	162,554
Cash flows used in financing activities:		
Decrease in short-term borrowings	-	(20,000)
Decrease in long-term borrowings	-	(14,093)
Payments of lease liabilities	(9,174)	(5,450)
Dividends paid	(49,150)	(61,437)
Net cash flows used in financing activities	(58,324)	(100,980)
Effect of fluctuations in exchange rate	69	2
Net increase in cash and cash equivalents	8,521	77,268
Cash and cash equivalents at beginning of period	576,585	488,904
Cash and cash equivalents at end of period	\$ 585,106	566,172

See accompanying notes to financial statements.

(English Translation of the Consolidated Financial Statements Originally Issued in Chinese)
TSH BIOPHARM CORPORATION LTD. and Subsidiaries
Notes to the Consolidated Financial Statements
September 30, 2024 and 2023

(Amounts expressed in thousands of New Taiwan Dollars unless otherwise specified)

1. History and organization

TSH Biopharm Corporation Ltd. (the “Company”) was incorporated on September 21, 2010. The Company's registered office address is 3F.-1, No. 3-1, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). The shares of the Company have been listed on the Taipei Exchange (“TPEX”) since April 2012. The main activity of the Company and its subsidiaries (the “Group”) is in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services.

2. Approval date and procedures of the financial statements

The accompanying consolidated financial statements were authorized for issue by the Board of Directors on November 8, 2024.

3. Application of new standards, amendments and interpretations

(1) The impact of the International Financial Reporting Standards (“IFRSs”) endorsed by the Financial Supervisory Commission, R.O.C. (“FSC”) which have already been adopted.

The Group believes that the adoption of the following IFRSs from January 1, 2024 would not have any material impact on its consolidated financial statements.

- Amendments to IAS 1 “Classification of Liabilities as Current or Non-current”
- Amendments to IAS 1 “Non - current Liabilities with Covenants”
- Amendment to IAS 7 and IFRS 7 “Supplier Finance Arrangements”
- Amendments to IFRS 16 “ Lease Liability in a Sale and Leaseback”

(2) The impact of IFRS endorsed by the FSC which have not been adopted.

The Company believes that the adoption of the following IFRS, which took effect from January 1, 2025 would not have any material impact on its consolidated financial statements.

- Amendments to IAS 21 “Lack of Exchangeability”

(3) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The IASB has issued standards and interpretations that have not yet been endorsed by the FSC. The potential impact on the Group is as follows:

<u>Newly issued or revised standards</u>	<u>Major revisions</u>	<u>Effective Date of the Council's Publication</u>
IFRS 18 “ Presentation and Disclosure in Financial Statements”	The new standard introduces three types of income and expenses, two subtotal items in the income statement, and a single note regarding management performance measurement. These three amendments strengthen guidance on how information is disaggregated in financial statements, providing users with better and more consistent information, and will impact all companies.	January 1, 2027

Newly issued or revised standards	Major revisions	Effective Date of the Council's Publication
IFRS 18 “Presentation and Disclosure in Financial Statements”	<ul style="list-style-type: none"> • More Structured Income Statement: Under current standards, companies use different formats to express their operating results, making it difficult for investors to compare the financial performance of different companies. The new standard adopts a more structured income statement, introducing a subtotal of "operating profit" based on new definitions and stipulating that all income and expenses be classified into three new distinct categories based on the company's primary operating activities. • Management Performance Measurement (MPM): The new standard introduces the definition of Management Performance Measurement and requires companies to explain in a single note to the financial statements for each performance measure why it provides useful information, how it is calculated, and how the measure is adjusted to reconcile with the amounts recognized under International Financial Reporting Standards accounting standards. • More Detailed Information: The new standard includes guidance on how companies should enhance the grouping of information in financial statements. This includes guidance on whether information should be included in the primary financial statements or further disaggregated in the notes. 	January 1, 2027

The Group is currently assessing the impact of the aforementioned standards and interpretations on the financial position and operating results of the consolidated company. Relevant impacts will be disclosed upon completion of the assessment.

The Group anticipates that the following additional yet to be endorsed new releases and amendments will not have a significant impact on the consolidated financial statements.

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of

Financial Instruments”

- Annual Improvements to IFRS Accounting Standards

4. Summary of significant accounting policies

(1) Statement of compliance

The accompanying consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and IAS 34, Interim Financial Reporting, as endorsed and issued into effect by the FSC. These consolidated financial statements do not present all the disclosures required for a complete set of annual consolidated financial statements prepared under the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations endorsed and issued into effect by the Financial Supervisory Commission, R.O.C. (hereinafter referred to as “IFRSs endorsed by FSC”).

Excepted for the accounting policies mentioned below, the significant accounting policies adopted in the interim financial statements is the same as those in the financial statements for the year ended December 31, 2023. For the related information, please refer to Note 4 of the financial statements for the year ended December 31, 2023.

(2) Basis of consolidation

A. Subsidiaries included in the consolidated financial statements:

<u>Name of Investor</u>	<u>Name of subsidiary</u>	<u>Main Business Activities</u>	<u>Percentage of Ownership</u>			<u>Note</u>
			<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>	
TSH Biopharm Corporation Ltd.	Chuang Yi Biotech Co. Ltd.	Selling of health food	51.60%	51.60%	51.60%	Note
TSH Biopharm Corporation Ltd.	Top Pharm Medicalware Co., Ltd.	Selling of medicine and dietary supplement	51%	-%	-%	Note 1
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Food manufacturing industry	51%	-%	-%	Note 1
Chuang Yi Biotech Co. Ltd.	Immortal Fame Global Ltd.	General export trade and investment in various production enterprises	100%	100%	100%	
Immortal Fame Global Ltd.	Chuang Yi (Shanghai) Trading Co., Ltd	Selling of dietary supplement	100%	100%	100%	

Note : The Company participated the cash capital increase of Chuang Yi Biotech Co. Ltd. on November 24, 2023, and has cumulatively acquired 51.60% of Chuang Yi Biotech Co. Ltd., achieving significant control. Since TTY Biopharm Company Limited is the ultimate parent company of the Company and Chuang Yi Biotech Co. Ltd., the aforementioned transaction is an organizational reorganization under common control according to the Interpretation Letter No.301 issued by the Accounting Research and Development Foundation’(101), and regarded as an acquisition from the beginning. The Company reclassify financial asset at fair value through other comprehensive income to the equity method and restated the parent company only financial statements for the prior period. The profit or loss belong to former controlling shareholders record as “Equity attributable to former owner of business combination under common control”.

Note 1: On March 11, 2024, the Company acquired 51% of the issued and outstanding common shares of Top Pharm Medicalware Co., Ltd. and TOP Biological Technology Company Limited. by resolution of the board of directors, and completed the share delivery on April 9, 2024.

B. Subsidiaries not included in the consolidated financial statements: None.

(3) Business combination

The Group first gained control over another company through acquisition in the second quarter of 2024. Therefore, from the second quarter of 2024, the accounting policies related to business combinations will be applied.

The Group accounts for business combinations using the acquisition method. The goodwill arising from an acquisition is measured as the excess of the consideration transferred (which is generally measured at fair value) and the amount of non-controlling interest in the acquiree, both over the identifiable net assets acquired at the acquisition date. If the amount calculated above is a deficit balance, the Group recognized that amount as a gain on a bargain purchase in profit or loss immediately after reassessing whether it has correctly identified all of the assets acquired and all of the liabilities assumed.

All acquisition-related transaction costs are expensed as incurred, except for the issuance of debt or equity instruments.

For each business combination, the Group measures any non controlling interests in the acquiree either at fair value or at the non controlling interest's proportionate share of the acquiree's identifiable net assets, if the non controlling interests are present ownership interests and entitle their holders to a proportionate share of the acquiree's net assets in the event of liquidation. Other components of non controlling interests are measured at their acquisition-date fair values, unless another measurement basis is required by the IFRSs endorsed by the FSC.

(4) Classification of current and non-current assets and liabilities

The Group classifies an asset as current when any one of the following requirements is met. Assets that are not classified as current are non-current assets.

- A. It expects to realize the asset, or intends to sell or consume it, in its normal operating cycle;
- B. It holds the asset primarily for the purpose of trading;
- C. It expects to realize the asset within twelve months after the reporting period; or
- D. The asset is cash or cash equivalent (as explained in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Group classifies a liability as current when any one of the following requirements is met. Liabilities that are not classified as current are non-current liabilities.

- A. It expects to settle the liability in its normal operating cycle;
- B. It holds the liability primarily for the purpose of trading;
- C. The liability is due to be settled within twelve months after the reporting period; or
- D. It does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counterparty, result in its settlement by issuing equity instruments do not affect its classification.

(5) Income taxes

The Group measures and discloses interim period income tax expense in accordance with paragraph

B12 of IAS 34, Interim Financial Reporting.

Income tax expense for the period is best estimated by multiplying pre-tax income of the interim period by a projected annual effective tax rate, and is recognized as current tax expense.

Income taxes that are recognized directly in equity or other comprehensive income are measured in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases at the tax rates that are expected to be applied in the year in which the asset is realized or the liability is settled.

5. Significant accounting assumptions and judgments, and major sources of estimation uncertainty

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34, Interim Financial Reporting, as endorsed and issued into effect by the FSC requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates. Except as described below, in preparing the consolidated financial statements, critical accounting judgments and key sources of estimations and assumptions uncertainty used by management in the application of accounting policies are consistent with those described in Note 5 of the financial statements for the year ended December 31, 2023 :

(1) Acquisitions of subsidiaries

The fair value of the identifiable intangible assets acquired by the Group through the acquisition of the subsidiary is provisional, pending final evaluation. The fair value recognized by the Group is based on the interpretation of the target contracts, consideration of the possible adjudication outcomes, and supported by independent legal advice. The Group will continue to review the above matters during the measurement period. If new information obtained within one year of the acquisition date about facts and circumstances that existed at the acquisition date identifies adjustments to the above amounts or any additional provisions that existed at the acquisition date, then the accounting for the acquisition will be revised. Refer to note 6(5) for further description of the acquisitions of subsidiaries.

6. Explanation of significant accounts

Except for the following disclosure, the significant account disclosure in the consolidated financial statements don't have significant difference with those in the consolidated financial statements for the year ended December 31, 2023. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2023.

(1) Cash and cash equivalents

	September 30, 2024	December 31, 2023	September 30, 2023
Petty cash	\$ 173	220	190
Cash in banks	584,933	574,365	265,982
Time deposits	-	2,000	300,000
	<u>\$ 585,106</u>	<u>576,585</u>	<u>566,172</u>

A. The above cash and cash equivalents were not pledged as collateral.

B. Time deposits which do not meet the definition of cash equivalents are accounted for under other financial assets-current. As of September 30, 2024, December 31, 2023 and September 30 2023, the amount of time deposits were \$127,000, \$116,309 and \$116,829 respectively.

C. Please refer to note 6(21) for the foreign currency risk and sensitivity analysis of the financial assets of the Group.

(2) Financial assets at fair value through other comprehensive income

	<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Equity instruments at fair value through other comprehensive income :			
Current	\$ 98,307	79,228	72,384
Non - current	<u>183,009</u>	<u>182,475</u>	<u>184,768</u>
	<u>\$ 281,316</u>	<u>261,703</u>	<u>257,152</u>

A. Equity instruments at fair value through other comprehensive income

The Group holds such equity investments as long-term strategic investment that is not held for trading purposes; thus, they are designated as equity investment measured at fair value through other comprehensive income.

For the nine months ended on September 30, 2024, and 2023, the company sold certain financial assets designated at fair value through other comprehensive income. The fair value at the time of disposal was \$221,121 and \$9,121 respectively, and the net gain on disposal was \$208,176 and \$6,796 respectively. Therefore, the previous disposal gain has been transferred from other equity to retained earnings.

B. Please refer to note 6(21) for credit and market risk information.

C. The above financial assets were not pledged as collateral.

(3) Notes receivable and accounts receivable (including related parties)

	<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Notes receivable	\$ 11,405	14,471	14,653
Accounts receivable-measured at amortized cost	323,889	195,631	253,498
Less: Allowance for expected credit losses	<u>(3,463)</u>	<u>(1,770)</u>	<u>(3,788)</u>
	<u>\$ 331,831</u>	<u>208,332</u>	<u>264,363</u>

The Group applies the simplified approach to provide for its expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and the days past due, as well as forward looking information. The loss allowance provision was determined as follows:

	<u>September 30, 2024</u>		
	<u>Gross carrying amount</u>	<u>Weighted-average loss rate</u>	<u>Loss allowance provision</u>
Not past due	\$ 333,347	0%~1%	3,289
Past due 1~60 days	1,947	1%~11.52%	174
Past due 61~120 days	-	-	-
Past due 121~180 days	-	-	-
Past due 181~365 days	-	-	-
Past due over 365 days	-	-	-
	<u>\$ 335,294</u>		<u>3,463</u>

	December 31, 2023		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Not past due	\$ 209,506	0%~1%	1,730
Past due 1~60 days	562	1%~8.14%	20
Past due 61~120 days	-	-	-
Past due 121~180 days	14	2%	-
Past due 181~365 days	-	-	-
Past due over 365 days	20	2%~100%	20
	\$ 210,102		1,770

	September 30, 2023		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Not past due	\$ 265,493	0.4%~1%	1,732
Past due 1~60 days	589	1%	6
Past due 61~120 days	-	-	-
Past due 121~180 days	-	-	-
Past due 181~365 days	2,049	2%~100%	2,030
Past due over 365 days	20	100%	20
	\$ 268,151		3,788

The movement in the allowance for notes and accounts receivable was as follows:

	For the nine months periods ended September 30	
	2024	2023
Balance on January 1, 2024	\$ 1,770	5,648
Impairment losses recognized	1,693	-
Impairment losses reversed	-	(1,860)
Balance on September 30, 2024	\$ 3,463	3,788

The aforementioned notes and account receivables of the Group had not been pledged as collateral as of September 30 2024, December 31 2023 and September 30 ,2023.

(4) Inventories

	September 30, 2024	December 31, 2023	September 30, 2023
Merchandise	\$ 146,829	88,023	106,012
Work in progress and finished goods	1,226	-	-
Raw materials and supplies	53,105	47,969	56,872
Less: Allowance for inventory market decline and obsolescence	<u>(28,553)</u>	<u>(17,597)</u>	<u>(12,911)</u>
	\$ 172,607	118,395	149,973

The details of cost of goods sold were as follows:

	For the three months periods ended September 30,		For the nine months periods ended September 30,	
	2024	2023	2024	2023
Reclassification of inventory sold \$	200,779	142,945	376,478	283,115
Loss for market price decline and obsolescence of inventory (gain from recovery)	(567)	124	10,956	3,503
Loss on physical inventory	-	-	-	37
	<u>200,212</u>	<u>143,069</u>	<u>387,434</u>	<u>286,655</u>

During the nine months periods ended September 30, 2024 and 2023 and the year ended December 31, 2023, the aforesaid inventories were not pledged as collateral.

(5) Acquisition of subsidiary

On April 9, 2024 (the acquisition date), the Company acquired 51% of the outstanding shares of Top Pharm Medicalware Co., Ltd. and TOP Biological Technology Company Limited. for \$301,451 thousand, thereby gaining control over these companies. Consequently, the Group's equity in Top Pharm Medicalware Co., Ltd. and TOP Biological Technology Company Limited. increased to 51%. Top Pharm Medicalware Co., Ltd. and TOP Biological Technology Company Limited. are engaged in the manufacturing and promotion of health food products.

The acquisition of control over Top Pharm Medicalware Co., Ltd. and TOP Biological Technology Company Limited. has allowed the combined company to expand its operational scale, enhance its operational performance, and increase its competitiveness.

A. Transfer Pricing

	Top Pharm Medicalware	TOP Biological Technology
Cash	<u>\$ 257,121</u>	<u>44,330</u>

B. Identifiable assets acquired and liabilities assumed

Fair value details of identifiable assets acquired and liabilities assumed as of the acquisition date are as follows :

	Top Pharm Medicalware	TOP Biological Technology
Cash and cash equivalents	\$ 55,135	3,446
Notes receivable and accounts receivable	49,520	11,255
Inventories	5,185	7,584
Other financial assets	25,000	-
Property, plant and equipment	215	4,967
Right-of-use assets	4,955	1,949
Intangible assets	318	-
Other non-current assets	2,894	3,640
Notes payable and accounts payable	(37,105)	(11,391)
Lease liabilities	(5,049)	(2,023)
Current tax liabilities	(5,356)	(1,182)
Other liabilities	(8,397)	(554)
	<u>\$ 87,315</u>	<u>17,691</u>

During the measurement period, the Group will continue to review the aforementioned matters. If new information related to facts and circumstances existing as of the acquisition date is obtained within one year from the acquisition date, which identifies adjustments to the provisional amounts or any additional liability reserves existing as of the acquisition date, the acquisition accounting will be revised accordingly.

C. Goodwill

The goodwill recognized from the acquisition is as follows:

	Top Pharm Medicalware	TOP Biological Technology
Transfer pricing	\$ 257,121	44,330
Add : Non-controlling interest (measure net identifiable assets in proportion to non-controlling interests)	42,784	8,669
Less : Fair value of net identifiable assets	<u>(87,315)</u>	<u>(17,691)</u>
Goodwill	<u>\$ 212,590</u>	<u>35,308</u>

D. Simulated information on business performance

From April 9, 2024, the business performance of Top Pharm Medicalware Co., Ltd. and TOP Biological Technology Company Limited. has been included in the consolidated comprehensive income statement of the Group. The net operating revenue contributed from April 9, 2024, to September 30, 2024, was \$175,014 thousand, and the net profit after tax was \$26,071 thousand.

If this acquisition had occurred on January 1, 2024, the pro forma net operating revenue of the Group from January 1, 2024, to September 30, 2024, would have been \$901,777 thousand, and the net profit after tax would have been \$126,248 thousand.

(6) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

<u>Subsidiaries</u>	<u>Main operation place</u>	<u>Percentage of non- controlling interests</u>		
		<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Chuang Yi Biotech Co. Ltd.	Taiwan	48.40%	48.40%	48.40%
Top Pharm Medicalware Co., Ltd.	"	49.00%	-%	-%
TOP Biological Technology Company Limited.	"	49.00%	-%	-%

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in these information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intragroup transactions were not eliminated in this information.

A. Chuang Yi Biotech Co. Ltd.'s collective financial information

	September 30, 2024	December 31, 2023	September 30, 2023
Current assets	\$ 441,006	343,428	280,875
Non-current assets	39,850	47,805	50,500
Current liabilities	(141,598)	(63,479)	(171,801)
Non- current liabilities	(25)	-	(679)
Net assets	<u>\$ 339,233</u>	<u>327,754</u>	<u>158,895</u>
Net assets attributed to non-controlling interests	<u>\$ 164,189</u>	<u>158,633</u>	<u>76,905</u>

	For the three months periods ended September 30,		For the nine months periods ended September 30,	
	2024	2023	2024	2023
Sales revenue	<u>\$ 169,588</u>	<u>145,711</u>	<u>222,565</u>	<u>216,683</u>
Net income	\$ 34,432	20,542	11,385	334
Other comprehensive income	36	68	93	3
Comprehensive income	<u>\$ 34,468</u>	<u>20,610</u>	<u>11,478</u>	<u>337</u>
Loss, attributable to non-controlling interests	<u>\$ 16,665</u>	<u>9,944</u>	<u>5,510</u>	<u>163</u>
Comprehensive income, attributable to non-controlling interests	<u>\$ 16,682</u>	<u>9,976</u>	<u>5,555</u>	<u>164</u>

	For the nine months periods ended September 30, 2024	For the nine months periods ended September 30, 2023
Net cash flows from operating activities	\$ 7,041	362
Net cash flows from investing activities	11	(26)
Net cash flows from financing activities	-	(36,186)
Effect of exchange rate changes on cash and cash equivalents	92	(121)
Net decrease in cash and cash equivalents	<u>\$ 7,144</u>	<u>(35,971)</u>

B. Top Pharm Medicalware Co., Ltd.'s collective financial information

	September 30, 2024
Current assets	\$ 167,376
Non-current assets	223,699
Current liabilities	(62,911)
Non- current liabilities	(5,305)
Net assets	<u>\$ 322,859</u>
Net assets attributed to non-controlling interests	<u>\$ 54,032</u>

	From July 1, 2024 to September 30, 2024	From April 9, 2024 to September 30, 2024
Sales revenue	<u>\$ 92,137</u>	<u>175,700</u>
Net income	\$ 11,038	22,954
Other comprehensive income	-	-
Comprehensive income	<u>\$ 11,038</u>	<u>22,954</u>
Net income attributable to non-controlling interests	<u>\$ 5,409</u>	<u>11,247</u>
Net cash flows from operating activities		\$ 19,877
Net cash flows from investing activities		898
Net cash flows from financing activities		<u>(4,710)</u>
Net increase in cash and cash equivalents		<u>\$ 16,065</u>

C. TOP Biological Technology Company Limited. 's collective financial information

	<u>September 30, 2024</u>
Current assets	\$ 26,095
Non-current assets	41,952
Current liabilities	(11,245)
Non- current liabilities	-
Net assets	<u>\$ 56,802</u>
Net assets attributed to non-controlling interests	<u>\$ 10,532</u>

	From July 1, 2024 to September 30, 2024	From April 9, 2024 to September 30, 2024
Sales revenue	<u>\$ 16,366</u>	<u>32,329</u>
Net income	\$ 1,504	3,804
Other comprehensive income	-	-
Comprehensive income	<u>\$ 1,504</u>	<u>3,804</u>
Net income attributable to non-controlling interests	<u>\$ 737</u>	<u>1,864</u>
Net cash flows from operating activities		\$ (2,595)
Net cash flows from financing activities		(352)
Net increase in cash and cash equivalents		<u>(1,078)</u>
Net cash flows from operating activities		<u>\$ (4,025)</u>

(7) Property, plant and equipment

	<u>Land</u>	<u>Building and construction</u>	<u>Machinery equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Total</u>
Cost:						
Balance on January 1, 2024	\$ 5,846	14,195	12,845	9,641	10,641	53,168
Acquired through business acquisitionr	-	-	9,591	1,096	9,774	20,461
Additions	-	-	392	102	353	847
Disposals	-	-	(635)	(3)	-	(638)
Effect of exchange rate changes	-	-	20	-	-	20
Balance on September 30, 2024	<u>\$ 5,846</u>	<u>14,195</u>	<u>22,213</u>	<u>10,836</u>	<u>20,768</u>	<u>73,858</u>
Balance on January 1, 2023	\$ 5,846	13,938	10,908	9,856	10,641	51,189
Additions	-	-	1,644	122	-	1,766
Reclassification	-	-	-	(215)	-	(215)
Effect of exchange rate changes	-	-	1	-	-	1
Balance on September 30, 2023	<u>\$ 5,846</u>	<u>13,938</u>	<u>12,553</u>	<u>9,763</u>	<u>10,641</u>	<u>52,741</u>
Accumulated depreciation and impairment losses:						
Balance on January 1, 2024	\$ -	5,619	8,333	6,860	6,997	27,809
Acquired through business acquisitionr	-	-	5,580	938	8,761	15,279
Depreciation	-	653	2,050	998	1,063	4,764
Disposals	-	-	(193)	(3)	-	(196)
Effect of exchange rate changes	-	-	19	-	-	19
Balance on September 30, 2024	<u>\$ -</u>	<u>6,272</u>	<u>15,789</u>	<u>8,793</u>	<u>16,821</u>	<u>47,675</u>
Balance on January 1, 2023	\$ -	4,769	7,193	5,883	6,333	24,178
Depreciation	-	634	664	930	401	2,629
Disposals	-	-	-	(198)	-	(198)
Effect of exchange rate changes	-	-	1	-	-	1
Balance on September 30, 2023	<u>\$ -</u>	<u>5,403</u>	<u>7,858</u>	<u>6,615</u>	<u>6,734</u>	<u>26,610</u>
Book value :						
Balance on January 1, 2024	<u>\$ 5,846</u>	<u>8,576</u>	<u>4,512</u>	<u>2,781</u>	<u>3,644</u>	<u>25,359</u>
Balance on September 30, 2024	<u>\$ 5,846</u>	<u>7,923</u>	<u>6,424</u>	<u>2,043</u>	<u>3,947</u>	<u>26,183</u>
Balance on September 30, 2023	<u>\$ 5,846</u>	<u>8,535</u>	<u>4,695</u>	<u>3,148</u>	<u>3,907</u>	<u>26,131</u>

(8) Right-of-use assets

	Building and construction	Transportation Equipment	Total
Cost :			
Balance on January 1, 2024	\$ 17,630	-	17,630
Acquired through business acquisitionr	5,053	15,982	21,035
Additions	-	7,537	7,537
Decrease	(195)	(6,778)	(6,973)
Balance on September 30, 2024	<u>\$ 22,488</u>	<u>16,741</u>	<u>39,229</u>
Balance on January 1, 2023	\$ 17,630	-	17,630
Balance on September 30, 2023	<u>\$ 17,630</u>	<u>-</u>	<u>17,630</u>
Accumulated depreciation :			
Balance on January 1, 2024	\$ 10,314	-	10,314
Acquired through business acquisitionr	2,838	11,293	14,131
Depreciation	6,246	2,745	8,991
Decrease	(123)	(6,778)	(6,901)
Balance on September 30, 2024	<u>\$ 19,275</u>	<u>7,260</u>	<u>26,535</u>
Balance on January 1, 2023	\$ 2,997	-	2,997
Depreciation	5,488	-	5,488
Balance on September 30, 2023	<u>\$ 8,485</u>	<u>-</u>	<u>8,485</u>
Book value :			
Balance on January 1, 2024	<u>\$ 7,316</u>	<u>-</u>	<u>7,316</u>
Balance on September 30, 2024	<u>\$ 3,213</u>	<u>9,481</u>	<u>12,694</u>
Balance on September 30, 2023	<u>\$ 9,145</u>	<u>-</u>	<u>9,145</u>

(9) Intangible assets

The cost and amortization of the Group's intangible assets is below:

	Computer software	Patent and drug permit license	Drug distributio n license	Goodwill	Others	Total
Cost :						
Balance on January 1, 2024	\$ 4,609	14,600	70,000	-	-	89,209
Acquired through business acquisitionr (Note 6(5))	1,253	-	-	247,898	87	249,238
Additions	643	-	-	-	-	643
Balance on September 30, 2024	<u>\$ 6,505</u>	<u>14,600</u>	<u>70,000</u>	<u>247,898</u>	<u>87</u>	<u>339,090</u>
Balance on January 1, 2023	\$ 3,869	56,791	70,000	-	-	130,660
Additions	177	-	-	-	-	177
Reclassification	711	-	-	-	-	711
Disposals	(148)	(22,354)	-	-	-	(22,502)
Balance on September 30, 2023	<u>\$ 4,609</u>	<u>34,437</u>	<u>70,000</u>	<u>-</u>	<u>-</u>	<u>109,046</u>

	<u>Computer software</u>	<u>Patent and drug permit license</u>	<u>Drug distribution license</u>	<u>Goodwill</u>	<u>Others</u>	<u>Total</u>
Accumulated amortisation and impairment losses:						
Balance on January 1, 2024	\$ 2,568	4,223	28,782	-	-	35,573
Acquired through business acquisitionr (Note 6(5))	951	-	-	-	71	1,022
Amortisation	<u>1,025</u>	<u>2,205</u>	<u>4,756</u>	<u>-</u>	<u>4</u>	<u>7,990</u>
Balance on September 30, 2024	<u>\$ 4,544</u>	<u>6,428</u>	<u>33,538</u>	<u>-</u>	<u>75</u>	<u>44,585</u>
Balance on January 1, 2023	\$ 1,483	42,668	22,441	-	-	66,592
Amortisation	925	3,011	4,756	-	-	8,692
Disposals	<u>(148)</u>	<u>(22,354)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(22,502)</u>
Balance on September 30, 2023	<u>\$ 2,260</u>	<u>23,325</u>	<u>27,197</u>	<u>-</u>	<u>-</u>	<u>52,782</u>
Book value						
Balance on January 1, 2024	<u>\$ 2,041</u>	<u>10,377</u>	<u>41,218</u>	<u>-</u>	<u>-</u>	<u>53,636</u>
Balance on September 30, 2024	<u>\$ 1,961</u>	<u>8,172</u>	<u>36,462</u>	<u>247,898</u>	<u>12</u>	<u>294,505</u>
Balance on September 30, 2023	<u>\$ 2,349</u>	<u>11,112</u>	<u>42,803</u>	<u>-</u>	<u>-</u>	<u>56,264</u>

(10) Other current assets and other non-current assets

The details of other current assets and other non-current assets were as follows:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Other current financial assets	\$ 127,000	116,309	116,829
Other current assets	1,274	3,441	2,544
Long-term prepayments	6,417	6,417	6,417
Refundable deposits	<u>9,107</u>	<u>6,237</u>	<u>5,293</u>
	<u>\$ 143,798</u>	<u>132,404</u>	<u>131,083</u>

A. Other current financial assets were time deposits which did not meet the definition of cash equivalents. For further credit and market risk information, please refer to note 6(21).

B. The long-term prepayments primarily serve to acquire intangible assets, representing payments made before the intangible assets are ready for use. Please refer to Note 9 for detailed explanations regarding related unrecognized contractual commitments.

(11) Other payables

The details of other payables were as follows:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Salaries and compensation of employees and directors	\$ 43,242	33,250	27,223
Research expenses	4,752	550	3,550
Commission	1,260	1,406	1,284
Others	<u>39,099</u>	<u>31,532</u>	<u>32,930</u>
	<u>\$ 88,353</u>	<u>66,738</u>	<u>64,987</u>

(12) Long-term borrowings

The details of the short-term borrowings were as follows:

	September 30, 2023
Borrowings from bank- Due date is June 2024.	\$ 14,345
Less : current portion	(14,354)
Total	\$ -
Interest rate range	2.5%

The long-term borrowings of the Group did not have significant issuances, repurchases, or repayments during the period for the nine months periods ended September 30, 2024 and 2023. Please refer to Note 6(20) for details on interest expenses and other relevant information, and consult Note 6(12) of the consolidated financial statements for the year ended December 31, 2023 for further details.

(13) Lease liabilities

The carrying amounts of lease liabilities were as follows:

	September 30,		September 30,
	2024	December 31, 2023	2023
Current	<u>\$ 7,453</u>	<u>7,397</u>	<u>7,403</u>
Non-current	<u>\$ 5,305</u>	<u>-</u>	<u>1,825</u>

For the maturity analysis, please refer to note 6(21) financial instruments .

The amounts recognized in profit or loss were as follows:

	For the three months periods		For the nine months periods ended	
	ended September 30		September 30	
	2024	2023	2024	2023
Interest on lease liabilities	<u>\$ 150</u>	<u>40</u>	<u>296</u>	<u>143</u>
Expenses of short-term leases	<u>\$ 289</u>	<u>240</u>	<u>689</u>	<u>384</u>
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	<u>\$ 102</u>	<u>49</u>	<u>146</u>	<u>173</u>

The amounts recognized in the statement of cash flows for the Group were as follows:

	For the nine months periods ended	
	September 30	
	2024	2023
Total cash outflow for leases	<u>\$ 10,305</u>	<u>6,150</u>

A. Real estate leases

The Group leased buildings for its office and plant with lease term of 2 to 13.5 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

The lease payment of the plant contract is calculated on basis of the purchase quantity of the plant leased by the Group during the lease period. It is a variable lease payment that is not included in the measurement of the lease liability. Therefore, the Group will pay the relevant

lease payment during the lease period to recognize the expense.

B. Other leases

The Group lease office equipment with lease term of 0.5 to 5 years, these leases are leases of short-term or low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

(14) Employee benefits

Defined contribution plans

The Group allocates 6% of each employee's monthly wages to the labor pension personal account at the Bureau of Labor Insurance in accordance with the provisions of the Labor Pension Act. Under these defined contribution plans, the Group allocates a fixed amount to the Bureau of Labor Insurance without additional legal or constructive obligation.

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Cost of goods sold	\$ 59	-	59	-
Selling expenses	1,952	1,234	4,306	3,680
Administrative expenses	697	373	2,267	1,136
Research and development expenses	92	113	256	356
	<u>\$ 2,800</u>	<u>1,720</u>	<u>6,888</u>	<u>5,172</u>

(15) Income taxes

A. Income tax expense

Details of the Group's income tax expenses are as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Current income tax expense				
Current period	\$ 8,730	4,721	29,004	12,663
Adjustments to current income tax of prior periods	-	-	209	-
Income tax expenses	<u>\$ 8,730</u>	<u>4,721</u>	<u>29,213</u>	<u>12,663</u>

B. Status of income tax assessment

The Group's tax returns for the years through 2022 were assessed by the Taipei National Tax Administration.

(16) Capital and other equity

Except as described below, there were no significant changes in equity of the Group for the nine months periods ended September 30 2024 and 2023. Please refer to Note 6(16) in the consolidated financial statements for the year ended December 31, 2023 for relevant information..

A. Capital surplus

The balances of capital surplus were as following:

	<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Share Capital	\$ 458,977	458,977	458,977
Others	<u>577</u>	<u>523</u>	<u>534</u>
	<u>\$ 459,554</u>	<u>459,500</u>	<u>459,511</u>

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

B. Retained earnings

The Group's article of incorporation stipulates that Group's net earnings should first be used to offset the prior years' deficits, if any, before paying any income taxes. Of the remaining balance, 10% is to be appropriated as legal reserve, until the accumulated legal reserve equals the Group's paid-in capital. In addition, a special reserve in accordance with applicable laws and regulations shall also be set aside. Then, any remaining profit, together with any undistributed retained earnings, shall be distributed according to the proposal by the Board of Directors and submitted to the stockholders' meeting for approval.

To enhance the Group's financial structure and maintain investors' equity, the Group adopts a stable dividends policy in which earnings distribution cannot be less than 50% of distributable earnings, and cash dividends payment has to be over than 50% of the distribution.

(A) Legal reserve

When a Group incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

(B) Special reserve

The Group has set aside the same amount of special surplus reserve in accordance with the requirements of the Financial Supervisory Commission's Order No. 1010012865 dated April 6, 101. When distributing the distributable surplus, the Group will record the deduction for other shareholders' equity that occurred in the current year. The difference between the net amount of the item and the special surplus reserve balance mentioned in the previous paragraph shall be included in the special surplus reserve from the profit and loss of the current period and the undistributed surplus of the previous period. The special surplus reserve shall not be distributed. If the amount of deductions from other shareholders' equity is subsequently reversed, the reversed portion of the earnings may be distributed.

(C) Earnings distribution

The company resolved at the shareholders' annual meetings on May 24, 2024, and May 25, 2023, to distribute the profits for the fiscal years 2023 and 2022. The dividend amounts to be distributed to shareholders are as follows:

	For the year ended December 31,			
	2023		2022	
	Amount per share (dollars)	Total amount	Amount per share (dollars)	Total amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 1.28	<u>49,150</u>	1.60	<u>61,437</u>

C. Other equity interests

	Exchange differences on translation of foreign financial statements	Unrealized gains on financial assets measured at fair value through other comprehensive income	Total
Balance on January 1, 2024	(\$ 233)	55,793	55,560
Exchange differences on translation of foreign financial statements	48	-	48
Unrealized gains on financial assets measured at fair value through other comprehensive income	-	240,733	240,733
Disposal of equity instrument measured at fair value through other comprehensive income	-	(208,176)	(208,176)
Balance on September 30, 2024	<u>(\$ 185)</u>	<u>88,350</u>	<u>88,165</u>
Balance on January 1, 2023	\$ -	22,575	22,575
Unrealized gains on financial assets measured at fair value through other comprehensive income	-	35,462	35,462
Disposal of equity instrument measured at fair value through other comprehensive income	-	(6,796)	(6,796)
Balance on September 30, 2023	<u>\$ -</u>	<u>51,241</u>	<u>51,241</u>

D. Non-controlling interests

	For the nine months periods ended September 30	
	2024	2023
Begininig balance	\$ 158,633	76,742
Attributable to non-controlling interests:		
Net income(loss)	18,622	162
Exchange differences on translation of foreign financial statements	45	1
Increase on non-controlling interest	51,453	-
Ending balance	<u>\$ 228,753</u>	<u>76,905</u>

(17) Earnings per share

The calculation of basic earnings per share and diluted earnings per share were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Basic earnings per share				
Net income attributable to ordinary shareholders	<u>\$ 48,539</u>	<u>16,838</u>	<u>103,484</u>	<u>45,794</u>
Weighted-average number of ordinary shares	<u>38,398</u>	<u>38,398</u>	<u>38,398</u>	<u>38,398</u>
	<u>\$ 1.26</u>	<u>0.44</u>	<u>2.70</u>	<u>1.19</u>
Diluted earnings per share				
Net income attributable to ordinary shareholders (after adjustment of dilutive potential ordinary shares)	<u>\$ 48,539</u>	<u>16,838</u>	<u>103,484</u>	<u>45,794</u>
Weighted-average number of ordinary shares	38,398	38,398	38,398	38,398
Effect of dilutive potential ordinary shares				
Effect of employee share bonus	43	10	49	34
Weighted-average number of ordinary shares (after adjustment of dilutive potential ordinary shares)	<u>38,441</u>	<u>38,408</u>	<u>38,447</u>	<u>38,432</u>
	<u>\$ 1.26</u>	<u>0.44</u>	<u>2.69</u>	<u>1.19</u>

(18) Revenue from contracts with customers

A. Disaggregation of revenue

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Major products/service lines:				
Pharmaceuticals	\$ 234,923	158,199	607,797	461,623
Vaccine	137,662	102,217	138,838	101,068
Test	12,303	8,253	32,253	20,039
Services	<u>3,644</u>	<u>751</u>	<u>45,725</u>	<u>1,827</u>
	<u>\$ 388,532</u>	<u>269,420</u>	<u>824,613</u>	<u>584,557</u>

B. Contract balances

	<u>September 30, 2024</u>	<u>December 31, 2023</u>	<u>September 30, 2023</u>
Notes receivable	\$ 11,405	14,471	14,653
Accounts receivable (included related parties)	323,889	195,631	253,498
Less: Allowance for expected credit losses	(3,463)	(1,770)	(3,788)
Total	<u>\$ 331,831</u>	<u>208,332</u>	<u>264,363</u>
Contract liabilities	<u>\$ 3,436</u>	<u>1,842</u>	<u>3,943</u>

For details on notes receivable, accounts receivable and allowance for expected credit losses, please refer to note 6 (3).

The contract liabilities primarily relate to the deferred recognition of revenue relating to customer loyalty programs and the unearned sales revenue ,for which revenue is recognized when the performance obligation is satisfied. The amount of revenue recognized for the nine months periods ended September 30, 2024 and 2023 that were included in the contract liability balance at the beginning of the period were \$1,034 and \$2,617, respectively.

C. Customer contract explanation

The Group accepts product returns from sales channels such as clinics and pharmacies, and agrees to provide discounts to certain channels under specific conditions. Taking into account the accumulated experience, the Group estimates the expected return rate based on historical sales return information, and estimates the expected value of sales or allowances based on historical experience, thereby recognizing a refund liability.

(19) Remuneration to employees and directors

According to the Group's articles of incorporation, the Group should contribute 2% to 8% of annual profits as employee compensation and no more than 2% of annual profits as directors' remuneration when there is profit for the year. Directors' remuneration can only be settled in the form of cash. However, if the Group has accumulated deficits, the profit should be reserved to offset the deficit. The amount of employee compensation and directors' remuneration is reported to shareholders' meeting. The recipients of employee compensation may include the employees of the Group's affiliated companies who meet certain conditions.

For the three months and nine months periods ended September 30, 2024 and 2023, the Group estimated its employee compensation and directors' remuneration both amounting to \$1,126, \$474, \$2,585 and \$1,218 respectively. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the remuneration to employees and directors of each period, multiplied by the percentage of remuneration to employees, directors and supervisors as specified in the Group's articles of incorporation. These compensation and remunerations recognized as operating expenses during 2023 and 2022. Related information is available on the Market Observation Post System website.

If there is a difference between the actual distribution amount and the estimated amount in the following year, it will be accounted for as an adjustment according to accounting estimates, and such difference will be recognized in the profit or loss for the following year. In the event that the board of directors decides to issue stock as employee compensation, the basis for calculating the number of shares for stock-based compensation is determined based on the closing price of common shares on the day before the board of directors' decision, taking into account any adjustments for dividends and rights issues.

For the year ended December 31, 2024 and 2023, the Group estimated its employee compensation and directors' remuneration both amounting to \$1,523 and \$1,604, respectively. The amounts are identical to those of the actual distributions for 2023 and 2022. Related information is available on the Market Observation Post System website.

(20) Non-operating income and expenses

A. Interest income

The details of interest income were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Interest income from bank deposits	\$ <u>542</u>	<u>957</u>	<u>2,934</u>	<u>4,786</u>

B. Other income

The details of other income were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Rent income	\$ 154	29	289	88
Other income-other	79	17	384	74
	\$ <u>233</u>	<u>46</u>	<u>673</u>	<u>162</u>

C. Other gains and losses

The details of other gains and losses were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Foreign exchange gains (losses)	\$ (153)	922	647	904
Dividends income	6,528	6,464	6,528	6,464
Losses on disposal of property, plant and equipment	(192)	(17)	(192)	(17)
Others	(491)	(171)	(848)	(434)
Other gains and losses(net)	\$ <u>5,692</u>	<u>7,198</u>	<u>6,135</u>	<u>6,917</u>

D. Finance costs

The details of finance costs were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Interest expenses – Borrowing from bank	\$ 15	76	15	432
Interest expenses– Lease liabilities	150	40	296	143
	\$ <u>165</u>	<u>116</u>	<u>311</u>	<u>575</u>

(21) Financial instruments

Except as described below, there were no significant changes in the fair value of financial

instruments and the exposure to credit risk, liquidity risk, and market risk arising from financial instruments of the Group. Please refer to Note 6(21) of the consolidated financial statements for 2023 for relevant information.

A. Credit risk

(A) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

(B) Concentration of credit risk

The Group has a customer base that includes hospitals, medical centers, pharmacies, and clinics, which results in the Group having no significant concentration of credit risk. The Group regularly assesses the likelihood of accounts receivable collection and recognize allowance for doubtful accounts, and the impairment losses are always within management's expectations.

(C) Credit risk of accounts receivables and debt securities

For credit risk exposure of notes and accounts receivables, please refer to note 6 (3).

Other financial assets at amortized cost includes other receivables and time deposits. All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4 (7). There were no recognition and reversal of impairment losses for the nine months periods ended September 30, 2024 and 2023. The balance as of September 30, 2024 and 2023 are both zero.

B. Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>Within a year</u>	<u>2~3 years</u>	<u>4~5 years</u>
September 30, 2024					
Non-derivative financial liabilities					
Notes and accounts payable (including related parties)	\$ 147,175	147,175	147,175	-	-
Other payables	88,353	88,353	88,353	-	-
Lease liabilities	12,758	13,464	7,870	5,070	524
	<u>\$ 248,286</u>	<u>248,992</u>	<u>243,398</u>	<u>5,070</u>	<u>524</u>
December 31, 2023					
Non-derivative financial liabilities					
Notes and accounts payable (including related parties)	\$ 51,424	51,424	51,424	-	-
Other payables	66,738	66,738	66,738	-	-
Lease liabilities	7,397	7,457	7,457	-	-
	<u>\$ 125,559</u>	<u>125,619</u>	<u>125,619</u>	<u>-</u>	<u>-</u>

September 30, 2023	Carrying amount	Contractual cash flows	Within a year	2~3 years	4~5 years
Non-derivative financial liabilities					
Borrowings from bank	\$ 14,354	14,504	14,504	-	-
Notes and accounts payable (including related parties)	144,745	144,745	144,745	-	-
Other payables	64,987	64,987	64,987	-	-
Lease liabilities	9,228	9,321	7,457	1,864	-
	\$ 233,314	233,557	231,693	1,864	-

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amounts.

C. Currency risk

(A) Exposure to foreign currency risk

The Group's significant exposure to foreign currency risk were as follows:

	September 30, 2024			December 31, 2023			September 30, 2023		
	Foreign currency	Exchange rate	TWD	Foreign currency	Exchange rate	TWD	Foreign currency	Exchange rate	TWD
Financial assets									
Monetary items									
USD	\$ 164	31.65	5,188	928	30.705	28,466	539	32.27	17,406
CNY	-	-	-	2,358	4.327	10,205	2,358	4.415	10,412
HKD	341	4.075	1,390	340	3.929	1,336	339	4.123	1,397

(B) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents that is denominated in foreign currency. A strengthening (weakening) 1% of the TWD against the USD, CNY, and HKD as of September 30, 2024 and 2023 would have increased (decreased) the net profit after tax by \$53 and \$234 thousand, respectively. The analysis is performed on the same basis for both periods.

(C) Foreign exchange gain and loss on monetary items

Due to the variety of functional currencies in the Group, exchange gain or loss information on monetary items is disclosed on an aggregated basis. For the three months periods ended September 30 in 2024 and 2023, as well as for the nine months ended September 30 in 2024 and 2023, the foreign exchange gains and losses (including both realized and unrealized) were losses of \$153, gains of \$922, gains of \$647, and gains of \$904, respectively.

(D) Interest rate risk

Please refer to the notes on liquidity risk management and interest rate exposure of the Group's financial assets and liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets

outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 0.25% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 0.25 %, the Group's net income and net loss would have decreased / increased by \$22 for the nine months periods ended September 30, 2023, with all other variable factors remaining constant.

(E) Other market price risk

For the nine months periods ended September 30, 2024 and 2023, the sensitivity analysis for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss with all other variable factors remaining constant as illustrated below:

Prices of securities at the reporting date	For the nine months periods ended September 30,			
	2024		2023	
	Other comprehensive income after tax	Net income	Other comprehensive income after tax	Net income
Increasing 10%	\$ 28,132	-	25,715	-
Decreasing 10%	(\$ 28,132)	-	(25,715)	-

D. Fair value of financial instruments

(A) Categories of financial instruments and fair value hierarchy

The fair value of financial assets at fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy, were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

	September 30, 2024				
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed stocks	\$ 173,992	173,992	-	-	173,427
Domestic OTC stocks	98,307	98,307	-	-	98,307
Foreign unlisted stocks	9,017	-	-	9,017	9,017
Subtotal	281,316	272,299	-	9,017	281,316
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 585,106	-	-	-	-
Notes and accounts receivable (including related parties)	331,831	-	-	-	-
Other receivables(including related parties)	37,718	-	-	-	-
Other financial assets	127,000	-	-	-	-
Refundable deposits	9,107	-	-	-	-
Subtotal	1,090,762	-	-	-	-
Total	\$ 1,372,078	272,299	-	9,017	281,316

Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 147,175	-	-	-	-
Other payables	88,353	-	-	-	-
Lease liabilities	12,758	-	-	-	-
Total	\$ 248,286	-	-	-	-
December 31, 2023					
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed stocks	\$ 173,458	173,458	-	-	173,458
Domestic OTC stocks	79,228	79,228	-	-	79,228
Foreign unlisted stocks	9,017	-	-	9,017	9,017
Subtotal	261,703	252,686	-	9,017	261,703
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 576,585	-	-	-	-
Notes and accounts receivable (including related parties)	208,332	-	-	-	-
Other receivables (including related parties)	2,141	-	-	-	-
Other financial assets	116,309	-	-	-	-
Refundable deposits	6,237	-	-	-	-
Subtotal	909,604	-	-	-	-
Total	\$ 1,171,307	252,686	-	9,017	261,703
Financial liabilities at amortized cost					
Notes and accounts payable (including related parties)	\$ 51,424	-	-	-	-
Other payables	66,738	-	-	-	-
Lease liabilities	7,397	-	-	-	-
Total	\$ 125,559	-	-	-	-
September 30, 2023					
	Book Value	Fair Value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed stocks	\$ 173,392	173,392	-	-	173,392
Domestic OTC stocks	72,384	72,384	-	-	72,384
Foreign unlisted stocks	11,376	-	-	11,376	11,376
Subtotal	257,152	245,776	-	11,376	257,152
Financial assets measured at amortized cost					
Cash and cash equivalents	\$ 566,172	-	-	-	-
Notes and accounts receivable (including related parties)	264,363	-	-	-	-
Other receivables (including related parties)	2,252	-	-	-	-
Other financial assets	116,829	-	-	-	-
Refundable deposits	5,293	-	-	-	-
Subtotal	954,909	-	-	-	-
Total	\$ 1,212,061	245,776	-	11,376	257,152

Financial liabilities at amortized cost					
Borrowing from bank	\$	14,354			
Notes and accounts payable (including related parties)		144,745	-	-	-
Other payables		64,987	-	-	-
Lease liabilities		9,228			
Total	\$	<u>233,314</u>	<u>-</u>	<u>-</u>	<u>-</u>

(B) Fair value hierarchy

The table below analyzes financial instruments carried at fair value by the levels in the fair value hierarchy. The different levels have been defined as follows:

- Level 1: quoted prices (unadjusted) in active markets for identified assets or liabilities.
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

(C) Valuation techniques for financial instruments not measured at fair value

The Group estimates its financial instruments, that are not measured at fair value, by methods and assumption as follows:

Cash and cash equivalents, accounts receivables, other financial assets, notes payable and accounts payable are either close to their expiry date, or their future receivable or payable are close to their carrying value; thus, their fair value are estimated from the book value of the balance sheet date.

- Financial assets measured at amortized cost

If the quoted prices in active markets are available, the market price is established as the fair value. However, if quoted prices in active markets are not available, the estimated valuation or prices used by competitors are adopted.

- Financial assets and financial liabilities measured at amortized cost

If there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimate fair values.

(D) Valuation techniques for financial instruments measured at fair value

Financial instruments traded in active markets are based on quoted market prices. The quoted price of a financial instrument obtained from main exchanges and on-the-run bonds from Taipei Exchange can be used as a basis to determine the fair value of the listed companies' equity instrument and debt instrument of the quoted price in an active market.

If a quoted price of a financial instrument can be obtained in time and often from exchanges, brokers, underwriters, industrial union, pricing institute, or authorities, and such price can reflect those actual trading and frequently happen in the market, then the financial instrument is considered to have a quoted price in an active market. If a financial instrument is not in accordance with the definition mentioned above, then it is considered to be without a quoted price in an active market. In general, market with low trading volume or high bid-ask spreads is an indication of a non-active market.

The fair value of the financial instruments held by the Group are determined by reference to

the market quotation.

If the financial instruments held by the Group have no active market, their fair values are listed as follows according to their categories and attributes:

- Equity instruments without public quotation: The fair value is measured by using the transaction prices of the stocks of companies engaged in the same or similar businesses in the active market, the value multipliers implied by these prices, and related transaction information to determine the value of the financial instruments, as well as adjusted for considering liquidity discount.

(E) Transfer between levels

There was no change in valuation techniques for financial instruments measured at fair value for the nine months periods ended September 30, 2024 and 2023, so there was no transfer between levels.

(F) Reconciliation of level 3 fair values:

	Fair value through other comprehensive income
	Equity instruments without quoted price
Balance as of January 1, 2024	\$ 9,017
Balance as of September 30, 2024	\$ 9,017
Balance as of January 1, 2023	\$ 11,376
Balance as of September 30, 2023	\$ 11,376

(G) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include financial assets at fair value through other comprehensive income - equity investments.

The majority of fair values of the Group are classified as Level 3, with only a single significant unobservable input, while equity investments without active market are characterized by multiple significant unobservable inputs. The significant unobservable inputs of the equity investments without an active market are individually, and there is no correlation between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Financial assets at fair value through other comprehensive income—equity investments without an active market	Comparable companies method	<ul style="list-style-type: none"> ·Discount for lack of market liquidity (as of September 30, 2024, December 31, 2023 and September 30, 2023, the rate were 30% ,30% and 16.43%, respectively) ·Expected volatility (as of September 30, 2023 was 58.78%) 	<ul style="list-style-type: none"> ·The estimated fair value would decrease if the discount for lack of market liquidity was higher. ·The estimated fair value would increase if the volatility was higher.

(H) Fair value measurements in Level 3 – sensitivity analysis of reasonably possible alternative assumptions

The Group's measurement on the fair value of financial instruments is deemed reasonable. However, use of different valuation models or assumptions may lead to different results. The following is the effect on other comprehensive income from financial assets categorized within Level 3 if the inputs used to valuation models have changed:

	<u>Input value</u>	<u>Degree of variation</u>	<u>Recognized in other comprehensive income</u>	
			<u>Favourable change</u>	<u>Unfavourable change</u>
September 30, 2024				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	90 (90)
December 31, 2023				
Financial assets at fair value through other comprehensive income				
Equity investments without an active market	Market liquidity discount rate	1%	90 (90)
September 30, 2023				
Equity investments without an active market	Market liquidity discount rate	1%	114 (114)
	Expected volatility	1%	39	39

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the interrelationships with another input.

(22) Financial risk management

There have been no significant changes to the financial risk management objectives and policies of the Group as disclosed in Note 6(22) of the financial statements for the year ended December 31, 2023.

(23) Capital management

The capital management objectives, policies, and procedures of the consolidated company remain consistent with those disclosed in the consolidated financial statements for the year ended December 31, 2023. Additionally, there have been no significant changes to the aggregated quantitative data for items related to capital management as disclosed in the consolidated financial statements for the year ended December 31, 2023. Please refer to Note 6(23) of the consolidated financial statements for the year ended December 31, 2023 for relevant information.

(24) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow for the nine months periods ended September 30, 2024 and 2023, were as follows:

A. Acquisition of right-of-use assets under leases, please refer to note 6(8).

B. Reconciliation of liabilities arising from financing activities were as follows:

	January 1, 2024	Cash flow	Non-cash changes	
			Others	September 30, 2024
Lease liabilities	\$ 7,397	(9,174)	14,535	12,758

	January 1, 2023	Cash flow	Non-cash changes	
			Others	September 30, 2023
Long-term borrowings	\$ 28,447	(14,093)	-	14,354
Short-term borrowings	20,000	(20,000)	-	-
Lease liabilities	14,678	(5,450)	-	9,228
Total liabilities arising from financing activities	\$ 63,125	(39,543)	-	23,582

7. Related-party transactions

(1) Parent company and ultimate controlling company

TTY Biopharm Company Limited is both the parent company and the ultimate controlling party of the Group. It owns 56.48% of all shares outstanding of the Group, and has issued the consolidated financial statements available for public use.

(2) Names and relationship with related parties

The followings are entities that have transactions with related party during the periods covered in the financial statements.

Name of related parties	Relationship with the Group
TTY Biopharm Company Limited	Parent company
American Taiwan Biopharm(Thailand)	Other related party
Shangta Pharmaceutical Co., Ltd.	Other related party (Note)

Note : Shangta Pharmaceutical Co., Ltd. was not related party since January, 2024.

(3) Significant related-party transactions

A. Operating revenue

The amounts of significant sales by the Group to its related parties were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Parent company- TTY Biopharm Company Limited	\$ 3,645	751	5,726	1,827
Other related parties	2,268	2,232	4,448	6,697
	<u>\$ 5,913</u>	<u>2,983</u>	<u>10,174</u>	<u>8,524</u>

The selling price and payment terms to related parties were not significantly different from those of sales to third parties. The collection terms for sales to related parties were month-end 60-90 days, or 14 days after the date of shipment. The collection terms for commission were month-end 30 and 90 days.

B. Purchases

The amounts of significant purchases by the Group from related parties were as follows:

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Parent company - TTY Biopharm Company Limited	<u>\$ 123,406</u>	<u>139,882</u>	<u>204,753</u>	<u>209,515</u>

The pricing and payment terms with related parties were not materially different from those of purchases with third parties. The payment terms for purchases from related parties were month-end 30-90 days.

C. Receivables from related parties

The amounts of receivables from related parties were as follows:

Items	Related Party Categories	September 30, 2024	December 31, 2023	September 30, 2023
Accounts receivable	Parent company	\$ 3,534	652	432
Accounts receivable	Other related party	-	114	2,234
		<u>\$ 3,534</u>	<u>766</u>	<u>2,666</u>

D. Payables to related parties

The amounts of payables to related parties were as follows:

Items	Related Party Categories	September 30, 2024	December 31, 2023	September 30, 2023
Accounts payable	Parent company	\$ 115,932	44,248	130,559
Other payables	Parent company	2,322	2,454	1,965
Other payables	Other related party	-	19	7
		<u>\$ 118,254</u>	<u>46,721</u>	<u>132,531</u>

E. Guarantee

On September 30, 2023, the Group has utilized the full amount of a \$50,000 loan from the bank, which was guaranteed by the parent company TTY Biopharm Company Limited. The parent company TTY Biopharm Company Limited charged an endorsement guarantee fee of \$229 for the nine months periods ended September 30, 2023.

F. Lease

The Group leases offices and equipments from the parent company, and the details were as follows:

Items	September 30, 2024	December 31, 2023	September 30, 2023	
Guarantee deposits paid	\$ <u>788</u>	<u>805</u>	<u>805</u>	
Lease liabilities	\$ <u>1,179</u>	<u>4,786</u>	<u>5,971</u>	
	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Interest paid	\$ <u>8</u>	<u>28</u>	<u>38</u>	<u>97</u>

G. Others

The operating expenses paid by the Group to the parent company due to the operating and business transactions were as follows:

Items	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Operating expenses	\$ <u>1,683</u>	<u>2,189</u>	<u>4,940</u>	<u>5,772</u>

(4) Key management personnel compensation

	For the three months periods ended September 30		For the nine months periods ended September 30	
	2024	2023	2024	2023
Short-term employee benefits	\$ 10,630	7,805	32,724	22,453
Post-employment benefits	<u>307</u>	<u>223</u>	<u>944</u>	<u>619</u>
	<u>\$ 10,937</u>	<u>8,028</u>	<u>33,668</u>	<u>23,072</u>

8. Pledged assets: None.

9. Significant commitments and contingencies

As of September 30, 2024, December 31, 2023 and September 30, 2023, the unrecognized contractual commitments of the Group were as follows:

	September 30, 2024	December 31, 2023	September 30, 2023
Contract with other units for research and development	\$ <u>20,233</u>	<u>43,505</u>	<u>43,739</u>
Acquisition of intangible assets	\$ <u>4,458</u>	<u>4,310</u>	<u>4,945</u>

10. Losses due to major disasters: None.

11. Subsequent events: None.

12. Others

(1) The followings are the summary of employee benefits, depreciation, and amortization by function :

By function	For the three months periods ended September 30,					
	2024			2023		
	Operating cost	Operating expenses	Total	Operating cost	Operating expenses	Total
By item						
Employee benefits						
Salary	2,728	52,883	55,611	-	38,453	38,453
Labor and health insurance	119	3,522	3,641	-	2,934	2,934
Pension	59	2,741	2,800	-	1,720	1,720
Others	50	2,231	2,281	-	1,470	1,470
Depreciation	580	4,696	5,276	-	2,722	2,722
Amortization	-	2,699	2,699	-	2,630	2,630

By function	For the nine months periods ended September 30,					
	2024			2023		
	Operating cost	Operating expenses	Total	Operating cost	Operating expenses	Total
By item						
Employee benefits						
Salary	2,728	140,341	143,069	-	112,216	112,216
Labor and health insurance	119	10,841	10,960	-	8,911	8,911
Pension	59	6,829	6,888	-	5,172	5,172
Others	50	4,786	4,836	-	3,825	3,825
Depreciation	1,133	12,622	13,755	-	8,117	8,117
Amortization	-	7,990	7,990	-	8,692	8,692

(2) Others:

The Group donated \$3,536, \$4,442, \$9,452 and \$8,249 to related medical foundation and associations to support non-profit organizations developing drugs, promoting disease prevention and correct dosages for the three months and nine months ended September 30, 2024 and 2023, respectively.

(3) Seasonality of operations

The operations of the Group are not affected by seasonal or cyclical factors.

13. Other disclosures

(1) Information on significant transactions

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group

A. Loans to other parties: None.

B. Guarantees and endorsements for other parties: None.

C. Securities held as of September 30, 2024 (excluding those investments in subsidiaries, associates and joint ventures):

(In Thousands of New Taiwan Dollars/Thousands shares)

Name of holder	Category and name of security	Relationship with Group	Account title	Ending balance				Note
				Shares/Units (thousands)	Carrying value	Percentage of ownership (%)	Fair value	
TSH Biopharm Corporation Ltd.	Lumosa Therapeutics Co., Ltd.	-	Current financial assets at fair value through other comprehensive income	297	98,307	0.18%	98,307	
"	Fubon Financial Holding Co., Ltd. Preferred stock B	-	Non-current financial assets at fair value through other comprehensive income	2,500	150,000	0.38%	150,000	
"	Union Bank of Taiwan Preferred stock A	-	"	400	20,960	0.20%	20,960	
"	Fubon Financial Holding Co., Ltd. Preferred stock C	-	"	58	3,032	0.02%	3,032	
"	CellMax Ltd.	-	"	1,593	9,017	-%	9,017	

D. Individual securities acquired or disposed of with an accumulated amount exceeding the lower of NT\$300 million or 20% of the capital stock:

Purchaser /seller	Category and name of security	Account title	Counter-party	Nature of Relationship	Beginning Balance		Acquisition-		Disposal				Ending Balance	
					Shares	Amount	Shares	Amount	Shares	Amount	Carrying Amount	Gain/ Loss on Disposal	Shares	Amount
TSH Biopharm Corporation Ltd.	Top Pharm Medicalware Co., Ltd.	Investments accounted for using equity method	High-End International Consultants Co., Ltd. and 12 others.	Non-Related parties	-	-	2,157	257,121	-	-	-	-	2,157	266,972
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Investments accounted for using equity method	High-End International Consultants Co., Ltd. and 5 others.	Non-Related parties -	-	-	510	44,330	-	-	-	-	510	46,270
TSH Biopharm Corporation Ltd.	LUMOSA THERAPEUTIC CO., LTD.	Current financial assets at fair value through other comprehensive income	-	-	1,160	79,228	-	-	863	221,121	12,954	208,176	297	98,307 (Note)

(In Thousands of New Taiwan Dollars/ Thousands shares)

Note: The ending balance is based on fair value valuation.

- E. Acquisition of individual real estate with amount exceeding the lower of NT\$300 million or 20% of the capital stock: None.
- F. Disposal of individual real estate with amount exceeding the lower of NT\$300 million or 20% of the capital stock: None.
- G. Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:

Company Name of Purchases or Sales of Goods	Counterparty	Relationship	Transaction details				Conditions of the transaction that differ from ordinary transactions, along with the reasons		Note receivable (payable), accounts receivable (payable)		Footnote
			Purchases or Sales of Goods	Amount	Percentage of total purchases or sales of goods	Credit period	Unit price	Credit period	Ending Balance	Percentage of total notes receivable (payable), accounts receivable (payable)	
Chuang Yi Biotech Co. Ltd.	TTY Biopharm Company Limited	Ultimate parent company	Purchase	147,106	95%	Monthly settlement, 90 days	Normal	Same as ordinary transaction	(111,038)	(97.54)%	

H. Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of the capital stock: None.

I. Trading in derivative instruments: None.

J. Business relationships and significant intercompany transactions:

Number	Trader's name	Counterparty	Relationship with the trader	Transaction details			
				Account title	Amount	Transaction conditions	Ratio of combined total revenue or total assets
0	TSH Biopharm Corporation Ltd.	Top Pharm Medicalware Co., Ltd.	1	Sales revenue	42,940	According to the contract terms	5.21%
1	TSH Biopharm Corporation Ltd.	Top Pharm Medicalware Co., Ltd.	1	Notes receivable	6,819	"	0.36%
1	TSH Biopharm Corporation Ltd.	Top Pharm Medicalware Co., Ltd.	1	Accounts receivable	7,291	"	0.38%
1	TOP Biological Technology Company Limited.	Top Pharm Medicalware Co., Ltd.	3	Accounts receivable	12,217	"	0.64%
1	TOP Biological Technology Company Limited.	Top Pharm Medicalware Co., Ltd.	3	Sales revenue	33,329	"	3.92%

Note 1、The numbering format is as follows：

1. 0 Representing the parent company.
2. Subsidiaries numbered sequentially starting from Arabic numeral 1.

Note 2、Types of relationships with the trader are indicated as follows:

1. Parent company to subsidiary.
2. Subsidiary to parent company
3. Subsidiary to subsidiary

Note 3、When preparing consolidated financial statements, all amounts have been fully offset.

Note 4、Individual amounts not exceeding \$1,000 thousand will not be disclosed, and their corresponding transactions will no longer be disclosed.

(2) Information on investees:

(In Thousands of New Taiwan Dollars/Thousands shares)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of September 30, 2024			Net Income (losses) of the investee	Share of Profits/ Losses of Investee	Footnote
				September 30, 2024	December 31, 2023	Shares (in Thousands)	Percentage of Ownership	Carrying Value			
TSH Biopharm Corporation Ltd.	Chuang Yi Biotech Co. Ltd.	Taiwan	Selling of health food	200,262	200,262	16,590	51.60%	175,044	11,385	5,875	
TSH Biopharm Corporation Ltd.	Top Pharm Medicalware Co., Ltd.	Taiwan	Selling of medicine and dietary supplement	257,121	-	2,157	51.00%	266,972	26,190	11,707	
TSH Biopharm Corporation Ltd.	TOP Biological Technology Company Limited.	Taiwan	Food manufacturing industry	44,330	-	510	51.00%	46,270	4,711	1,940	
Chuang Yi Biotech Co. Ltd.	Immortal Fame Global Ltd.	SAMOA	General export trade and investment in various production enterprises	16,820	16,820	568	100.00%	2,070	(186)	(186)	

Note : The aforementioned transactions were eliminated in the preparation of consolidated financial statements.

(3) Information on investment in mainland China:

A. The names of investees in Mainland China, the main businesses and products, and other information:

(In Thousands of New Taiwan Dollars/Thousands shares)

Investee Company	Main Businesses and Products	Total Amount of Paid-in Capital	Method of Investment (note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2024	For the nine months periods ended September 30, 2024		Accumulated Outflow of Investment from Taiwan as of September 30, 2024	Net Income (Losses) of the Investee Company	Percentage of Ownership	Share of Profits/Losses (note 2)	Carrying Amount as of September 30, 2024	Accumulated Inward Remittance of Earnings as of September 30, 2024
					Outflow	Inflow						
Chuang Yi (Shanghai) Trading Co., Ltd	Selling of health food	15,825 (USD 500)	(1)	15,825 (USD 500)	- USD -	-	15,825 (USD 500)	(191)	100%	(191)	2,028	-

USD Exchange Rate: End of period rate: 31.65 ; Average rate: 32.0242

RMB Exchange Rate: End of period rate: 4.5230 ; Average rate: 4.4462

Note 1 : Through the establishment of third-region companies, then investing in Mainland China.

Note 2 : The aforementioned transactions were eliminated in the preparation of consolidated financial statements.

Note 3 : The financial statements of Chuang Yi (Shanghai) Trading Co., Ltd had been reviewed by the CPA of the parent company in Taiwan.

B. Limitation on investment in Mainland China:

Accumulated Investment in Mainland China as of September 30, 2024	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
NTD 15,825 (USD 500)	NTD 15,825 (USD 500)	NTD 841,662

C. Significant transactions: None.

(4) Major shareholders:

Shareholder's name	Shareholding	Total shares owned	Percentage of ownership (%)
TTY Biopharm Company Limited		21,687,177	56.48%

14. Segment information

(1) General information

The Group's operating segments required to be disclosed are categorized as Domestic Cardiovascular Business Unit, Gastrointestinal Drugs Business Unit, and Investment Business Unit, etc.

The segments' profit is measured at profit before tax. The Group assesses performance of the segments based on the segments' profit. The operating segments' accounting policies are similar to those described in Note 4 "significant accounting policies"

(2) Information about reportable segments and their measurement and reconciliations

The Group's operating segment information and reconciliation are as follows:

	Domestic Cardiovascular and Gastrointestinal Drugs	Investment	Others	Adjustment and elimination	Total
For the 3 months ended September 30, 2024					
Revenue					
Revenue from External Customer	\$ 127,491	261,041	-	-	388,532
Interest revenue	20,706	684	-	(21,390)	-
Total	\$ 148,197	261,725	-	(21,390)	388,532
Reportable segment profit or loss	\$ 29,773	50,308	-	-	80,081
For the 3 months ended September 30, 2023					
Revenue					
Revenue from External Customer	\$ 123,709	145,711	-	-	269,420
Interest revenue	-	-	-	-	-
Total	\$ 123,709	145,711	-	-	269,420
Reportable segment profit or loss	\$ 21,559	20,542	-	-	42,101
For the 6 months ended September 30, 2024					
Revenue					
Revenue from External Customer	\$ 427,053	397,560	-	-	824,613
Interest revenue	42,940	705	-	(43,645)	-
Total	\$ 469,993	398,265	-	(43,645)	824,613
Reportable segment profit or loss	\$ 104,229	47,090	-	-	151,319
For the 6 months ended September 30, 2023					
Revenue					
Revenue from External Customer	\$ 367,874	216,683	-	-	584,557
Interest revenue	-	-	-	-	-
Total	\$ 367,874	216,683	-	-	584,557
Reportable segment profit or loss	\$ 58,457	334	-	-	58,791
Reportable segment assets					
30-Sep-24	\$ 1,228,234	677,155	-	-	1,905,389
30-Dec-24	\$ 1,008,626	391,233	-	-	1,399,859
30-Sep-23	\$ 1,147,155	331,375	-	-	1,478,530